About HEPALINK Company

The company was founded in 1998 in Shenzhen, China. “Bringing the gospel to patients is our mission and becoming a leading international pharmaceutical company” was the founder's intention. Continued and unremitting efforts have enabled Hyperion to establish an integrated safe supply chain, becoming the world's largest heparin sodium API company and the world's third largest enoxaparin formulation company. The company is a global pharmaceutical company based in China, with global business in the field of heparin sodium preparations and APIs, macromolecule drug CDMO, and innovative drug development. The main products and services include enoxaparin sodium preparations and heparin sodium APIs, enoxaparin sodium APIs, and macromolecule drug CDMO services. Corporate honors: It has successively undertaken national science and technology projects such as the National Biotech Industrialization Demonstration Project, the National Torch Program Project, and the National Key Technological Innovation Project, and has made important contributions to the technological progress, industrial upgrading, and improvement of the ability to generate foreign exchange in China's heparin industry. The company has successively won the “National Technological Innovation Outstanding New Product Award”, “Outstanding Contribution Enterprise to the Shenzhen Special Economic Zone”, “Shenzhen's Outstanding Private Enterprise”, and has become a key high-tech enterprise in the country and Shenzhen.